Use of the serum free light chain assay in assessment of response to therapy in multiple myeloma: Validation of recently proposed response criteria in a prospective clinical trial of lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.

被引：0
作者：
Kumar, S
Gertz, MA
Hayman, SR
Lacy, MQ
Dispenzieri, A
Zeldenrust, SR
Lust, JA
Greipp, PR
Kyle, RA
Fonseca, R
Rajkumar, SV
机构：
[1] Mayo Clin, Scottsdale, AZ USA
[2] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3479
引用
收藏
页码：971A / 971A
页数：1
相关论文
共 50 条
  • [21] Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
    Reeder, C. B.
    Reece, D. E.
    Kukreti, V.
    Chen, C.
    Trudel, S.
    Hentz, J.
    Noble, B.
    Pirooz, N. A.
    Spong, J. E.
    Piza, J. G.
    Zepeda, V. H. J.
    Mikhael, J. R.
    Leis, J. F.
    Bergsagel, P. L.
    Fonseca, R.
    Stewart, A. K.
    LEUKEMIA, 2009, 23 (07) : 1337 - 1341
  • [22] Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
    C B Reeder
    D E Reece
    V Kukreti
    C Chen
    S Trudel
    J Hentz
    B Noble
    N A Pirooz
    J E Spong
    J G Piza
    V H J Zepeda
    J R Mikhael
    J F Leis
    P L Bergsagel
    R Fonseca
    A K Stewart
    Leukemia, 2009, 23 : 1337 - 1341
  • [23] Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Bhutani, Manisha
    House, Monika
    He, Jiaxian
    Atrash, Shebli
    Foureau, David M.
    Paul, Barry
    Friend, Reed
    Symanowski, James T.
    Norek, Sarah
    Begic, Xhevahire
    Acampora, Donna
    Farmer, Katherine K.
    Syfert, Carrie Ann
    Pineda-Roman, Mauricio
    Voorhees, Peter
    Usmani, Saad Z.
    BLOOD, 2020, 136
  • [24] A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma.
    Rajkumar, S. Vincent
    Hussein, Mohamad
    Catalano, John
    Jedrzejcak, Wieslaw
    Sirkovich, Svetlana
    Olesnyckyj, Marta
    Yu, Zhinuan
    Knight, Robert
    Zeldis, Jerry
    Blade, Joan
    BLOOD, 2006, 108 (11) : 238A - 238A
  • [25] Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy
    Moustafa, M. Alhaj
    Rajkumar, S. V.
    Dispenzieri, A.
    Gertz, M. A.
    Lacy, M. Q.
    Buadi, F. K.
    Hwa, Y. L.
    Dingli, D.
    Kapoor, P.
    Hayman, S. R.
    Lust, J. A.
    Kyle, R. A.
    Kumar, S. K.
    LEUKEMIA, 2015, 29 (10) : 2033 - 2038
  • [26] Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.
    Tandon, Nidhi
    Lacy, Martha
    Buadi, Francis
    Leung, Nelson
    Go, Ronald S.
    Dingli, David
    Kapoor, Prashant
    Gertz, Morie A.
    Lin, Yi
    Dispenzieri, Angela
    Drake, Matthew
    Hwa, Yi Lisa
    Fonder, Arnie
    Hobbs, Miriam
    Hayman, Suzanne R.
    Zeldenrust, Steven R.
    Lust, John Anthony
    Gonsalves, Wilson I.
    Rajkumar, S. Vincent
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy
    M Alhaj Moustafa
    S V Rajkumar
    A Dispenzieri
    M A Gertz
    M Q Lacy
    F K Buadi
    Y L Hwa
    D Dingli
    P Kapoor
    S R Hayman
    J A Lust
    R A Kyle
    S K Kumar
    Leukemia, 2015, 29 : 2033 - 2038
  • [28] Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
    Rajkumar, S. Vincent
    Jacobus, Susanna
    Callander, Natalie S.
    Fonseca, Rafael
    Vesole, David H.
    Williams, Michael E.
    Abonour, Rafat
    Siegel, David S.
    Katz, Michael
    Greipp, Philip R.
    LANCET ONCOLOGY, 2010, 11 (01) : 29 - 37
  • [29] Phase III trial of thalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07) : 452 - 453
  • [30] Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma
    Tacchetti, Paola
    Rocchi, Serena
    Zamagni, Elena
    Barbato, Simona
    Rizzello, Ilaria
    De Cicco, Gabriella
    Pantani, Lucia
    Mancuso, Katia
    Fusco, Alessio
    Dozza, Luca
    Ursi, Margherita
    Favero, Emanuele
    Terragna, Carolina
    Testoni, Nicoletta
    Cavo, Michele
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (12) : 1607 - 1615
12345